GLP-1 and Fertility

GLP-1 medications improve fertility markers by reducing insulin resistance, restoring ovulatory cycles, and supporting weight loss — with critical implications for conception planning and contraception during treatment.

The relationship between body weight and fertility is well established. Obesity disrupts the hypothalamic-pituitary-ovarian axis in women, suppressing the normal hormonal signals that trigger ovulation.

In men, excess adipose tissue converts testosterone to estrogen, reducing sperm production and motility. GLP-1 receptor agonists address these problems primarily through medically significant weight loss.

Studies consistently show that weight loss of just 5% of body weight is sufficient to restore ovulatory cycles in a significant proportion of women with obesity-related anovulation. At 10% weight loss, the majority of women experience normalization of menstrual cycles.

GLP-1s — particularly semaglutide and tirzepatide — produce average weight losses of 15–22% in clinical trials, well above the threshold needed to restore reproductive function. In men, GLP-1-driven weight loss has been shown to significantly increase total and free testosterone, reduce estradiol, improve sperm motility and morphology, and restore libido.

These improvements emerge within 3–6 months of meaningful weight loss and continue to deepen as weight reduction progresses.

Whether you are using GLP-1 therapy as a pre-conception weight loss tool or monitoring your reproductive health during treatment, systematic tracking gives you and your healthcare team the data needed to optimize your plan.

Shotlee makes it easy to log injections, body weight, and notes in one place.

GLP-1 Drug Starting Dose Maintenance Dose Administration

Track every dose, monitor your progress, and optimize your GLP-1 outcomes with Shotlee — the free app built for GLP-1 users. 🚀 Use Shotlee for Free GLP-1 Tracker GLP-1 & PCOS Ozempic Tracker Wegovy Tracker